Sleep Halo Sleep Metrics Are Based on Masimo
W1’s Continuous Pulse Oximetry Measurements and Advanced Halo AI
Technology
Masimo (NASDAQ: MASI), today announced that the Masimo W1® Sport
advanced health tracking wearable is gaining a powerful new
feature: scientifically based sleep analysis with Sleep Halo™.
Sleep Halo offers overnight sleep data tracking with an unmatched
70,000+ daily measurements of second-by-second continuous health
data.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240701792393/en/
Masimo W1® with Sleep Halo™ (Graphic:
Business Wire)
Sleep Halo uses continuous Masimo pulse oximetry and machine
learning to provide meaningful insights into the quality of an
individual’s sleep, including overall timing, duration of sleep
stages, periods of rest and wakefulness, episodes of desaturation,
and more. The nightly analysis, including a Sleep Halo score – an
algorithmic calculation representing your overall sleep quality –
is visualized on the companion Masimo Health smartphone app. The
Sleep Halo score and sleep analysis will be featured in all future
Masimo wearables, including the upcoming Masimo Freedom™ Watch and
Band.
Joe Kiani, Founder and CEO of Masimo, said, “We’re truly excited
to launch Sleep Halo for Masimo W1 Sport. For 35 years, Masimo has
been dedicated to using breakthrough engineering to help improve
lives. Masimo W1 is unique among wearables in being able to
continuously measure the wearer’s SpO2 and PR – and that gives us
an opportunity to provide a truly informed, robust analysis of how
one sleeps. As always, we are committed to providing scientifically
backed measurements, which are based on our unmatched, accurate
technology, not ‘tarot card logic’ novelties. We benchmarked Sleep
Halo with EEG to confirm its stages of sleep are comparable to
sleep analysis. We hope that with this new scientifically based
Sleep Halo, our customers can improve their sleep hygiene, which
has been shown to improve life.”
Today’s consumers are limited to choosing from among a variety
of consumer wearables, which use intermittent and often inaccurate
data, heavily reliant on movement – which cannot provide reliable
or actionable sleep metrics. Masimo W1 – which has been shown to be
significantly more accurate than the leading consumer wearable1 –
is designed to provide sophisticated and insightful sleep analysis
using technology based on Masimo SET®, the primary pulse oximetry
technology at all top 10 U.S. hospitals as ranked in the 2024
Newsweek World’s Best Hospitals listing.2 Rigorously tested against
reference laboratory measurements, including EEG data, Sleep Halo
makes it possible to bring reliable, insightful sleep analysis to
everyday people around the world, on a nightly basis, via a
lightweight, comfortable wearable, from the convenience of their
own home.
Existing Masimo W1 Sport owners will soon be able to update
their watch firmware and Masimo Health app to begin their sleep
tracking journey. Masimo W1 is available for purchase at
www.Masimo.com.
Also available is Masimo W1 Medical, the first and only
FDA-cleared watch to provide continuous, real-time SpO2 and PR with
an indicator when measurements are outside of their normal
ranges.
Masimo W1 Sport and Sleep Halo are for general health and
wellness purposes.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.3
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,4 improve CCHD screening in
newborns,5 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.6-9 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,10 and is
the primary pulse oximetry at all 10 top U.S. hospitals as ranked
in the 2024 Newsweek World’s Best Hospitals listing.2 In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013,
Masimo introduced the Root® Patient Monitoring and Connectivity
Platform, built from the ground up to be as flexible and expandable
as possible to facilitate the addition of other Masimo and
third-party monitoring technologies; key Masimo additions include
Next Generation SedLine® Brain Function Monitoring, O3® Regional
Oximetry, and ISA™ Capnography with NomoLine® sampling lines.
Masimo’s family of continuous and spot-check monitoring Pulse
CO-Oximeters® includes devices designed for use in a variety of
clinical and non-clinical scenarios, including tetherless, wearable
technology, such as Radius-7®, Radius PPG®, and Radius VSM™,
portable devices like Rad-67®, fingertip pulse oximeters like
MightySat® Rx, and devices available for use both in the hospital
and at home, such as Rad-97® and the Masimo W1® Medical Watch.
Masimo hospital and home automation and connectivity solutions are
centered around the Masimo Hospital Automation™ platform, and
include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo
ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing
portfolio of health and wellness solutions includes Radius Tº® and
Masimo W1 Sport. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- Masimo internal whitepaper on file.
-
https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo W1® and Sleep
Halo™. These forward-looking statements are based on current
expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo W1 and Sleep Halo, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
the assumption that Sleep Halo will be available on future Masimo
wearables including Freedom™ Watch and Band; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701792393/en/
Media: Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
過去 株価チャート
から 9 2024 まで 10 2024
Masimo (NASDAQ:MASI)
過去 株価チャート
から 10 2023 まで 10 2024